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A four-center study in which a total of 1,082 recent clinical isolates of members of the family Enterobacte-
riaceae and Pseudomonas aeruginosa were examined versus 11 antimicrobial agents with the bioMerieux Vitek
susceptibility test system (Hazelwood, Mo.) and the GNS-F6 card was conducted. In addition, a challenge set
consisting of the same 200 organisms was examined in each of the four participating laboratories. Results
obtained with the Vitek system were compared to MICs determined by a standardized broth microdilution
method. For purposes of comparison, susceptibility categories (susceptible, intermediate, or resistant) were
assigned on the basis of the results of both methods. The result of the broth microdilution test was considered
definitive. The total category error rate with the Vitek system and the recent clinical isolates (11,902 organism-
antimicrobial comparisons) was 4.5%, i.e., 1.7% very major errors, 0.9% major errors, and 1.9% minor errors.
The total category error rate calculated from tests performed with the challenge set (i.e., 8,800 organism-
antimicrobial comparisons) was 5.9%, i.e., 2.2% very major errors, 1.1% major errors, and 2.6% minor errors.
Very major error rates higher than the totals were noted with Enterobacter cloacae versus ampicillin-sulbactam,
aztreonam, ticarcillin, and ticarcillin-clavulanate and with P. aeruginosa versus mezlocillin, ticarcillin, and
ticarcillin-clavulanate. Major error rates higher than the averages were observed with Proteus mirabilis versus
imipenem and with Klebsiella pneumoniae versus ofloxacin. Excellent overall interlaboratory reproducibility was
observed with the Vitek system. The importance of inoculum size as a primary determinant in the accuracy of
susceptibility test results with the Vitek system was clearly demonstrated in this study. Specifically, when an
inoculum density fourfold higher than that recommended by the manufacturer was used, high rates of false
resistance results were obtained with cell wall-active antimicrobial agents versus both the Enterobacteriaceae
and P. aeruginosa.
The Vitek system (bioMerieux Vitek, Hazelwood, Mo.) is an
automated method for performing same-day identification and
antimicrobial susceptibility tests on nonfastidious bacteria. It
was first introduced in 1979 and has received broad application
in clinical microbiology laboratories worldwide. Numerous
published reports have described the antimicrobial susceptibil-
ity testing capability of the Vitek system. Many of these studies
have addressed susceptibility testing of Enterococcus species
(2, 8, 16, 22–25, 27, 29) or staphylococci (3, 4, 7, 8, 14, 26, 30,
31). Several published investigations have described acceptable
levels of accuracy when the Vitek system was used to deter-
mine the antimicrobial susceptibility patterns of members of
the family Enterobacteriaceae and Pseudomonas aeruginosa (6,
9–11, 13, 19–21, 28, 32). A single exception might be detection
of extended-spectrum b-lactamase-producing Klebsiella and
Escherichia species with current test materials (12). Recently,
two reports that describe high rates of false resistance with
imipenem and aztreonam when selected Enterobacteriaceae
and Pseudomonas spp. were tested with the currently available
Vitek system have appeared (1, 15). Because of these two
reports, a prospective, controlled multicenter study was con-
ducted in an effort to assess the accuracy of the contemporary
Vitek system as a means for determining the antimicrobial
susceptibility of clinical isolates of facultative gram-negative
bacilli.
MATERIALS AND METHODS
Organisms tested. Between 231 and 320 unique patient isolates of Enterobac-
teriaceae and P. aeruginosa were examined in each of four medical centers: Good
Samaritan Hospital, Phoenix, Ariz.; Veterans Administration Medical Center,
Tampa, Fla.; University of Iowa Hospitals and Clinics, Iowa City, Iowa; and
Primary Children’s Medical Center, Salt Lake City, Utah (Table 1). In addition,
a collection of 200 common stock strains was examined in each center (Table 1).
Study design. Antimicrobial susceptibility tests were performed in each of four
laboratories using the GNS-F6 card and the bioMerieux Vitek instrument ac-
cording to the manufacturer’s instructions. Inocula of clinical isolates were pre-
pared directly from primary plates. The 200 isolates in the common challenge set
were tested after two subcultures. The following 11 antimicrobial agents were
used: ampicillin, ampicillin-sulbactam, aztreonam, ciprofloxacin, imipenem,
mezlocillin, ofloxacin, piperacillin, ticarcillin, ticarcillin-clavulanate, and tri-
methoprim-sulfamethoxazole (TMP-SMX). After testing, all of the clinical iso-
lates were shipped on tryptic soy agar slants to the University of Massachusetts
Medical Center (UMMC), where stock cultures were prepared and frozen at
270°C. Stock cultures of the challenge set were also maintained at UMMC at
270°C.
At UMMC, both clinical isolates and strains from the challenge set were
subsequently reconstituted from frozen stocks and subcultured twice on sheep
blood agar plates incubated at 35°C for 20 to 24 h, and MICs were determined
with the same 11 antimicrobial agents tested with the GNS-F6 card (see above).
* Corresponding author. Mailing address: Clinical Microbiology,
Department of Pathology, University of Iowa Hospitals and Clinics,
Iowa City, IA 52242. Phone: (319) 356-8616. Fax: (319) 356-4916.
2115
 at UNIV O
F M
ASS M
ED SCH on July 15, 2008 
jcm.asm.org
D
ow
nloaded from
 
MICs were determined by a microdilution method in cation-adjusted Mueller-
Hinton broth (100-ml final volume per well) according to the recommendations
of the National Committee for Clinical Laboratory Standards (NCCLS) (18).
The final inoculum concentration was ca. 5 3 105 CFU/ml. Antimicrobial pow-
ders were obtained from their respective manufacturers. The following control
organisms were employed: Escherichia coli ATCC 25922, E. coli ATCC 35218,
and P. aeruginosa ATCC 27853.
Categorization of errors. The susceptibility category (susceptible [S], interme-
diate [I], or resistant [R]) assigned to each organism-antimicrobial combination
by the Vitek system was taken as the Vitek result. The MIC results obtained with
the broth microdilution method were converted into susceptibility categories (S,
I, or R) according to the interpretive criteria of the NCCLS (18) and considered
to be definitive. Very major errors were defined as an S result with Vitek GNS-F6
and an R result according to the MIC, the opposite pattern was considered a
major error, and any other category discrepancy was defined as a minor error.
RESULTS
The results of testing of clinical isolates in the four partici-
pating laboratories are depicted in Table 2. Several observa-
tions could be made from these data. In general, there was
excellent concordance among the four laboratories with re-
spect to error rates for individual antimicrobial agents. Fur-
thermore, in no case either for data from individual laborato-
ries or for the data analyzed collectively was the aggregate
error rate (i.e., very major plus major plus minor errors) for a
specific agent found to exceed 10%. Three agents were found
to yield total aggregate error rates of ,3.0%: ciprofloxacin
(1.4%), ofloxacin (2.6%), and TMP-SMX (2.2%). Total aggre-
gate error rates of 3 to 7% were observed with seven drugs:
ampicillin (3.2%), aztreonam (4.6%), imipenem (3.4%), me-
zlocillin (6.2%), piperacillin (6.8%), ticarcillin (4.7%), and ti-
carcillin-clavulanate (6.5%). The final agent, ampicillin-sulbac-
tam, yielded a total aggregate error rate of 8.4%. The overall
aggregate error rate calculated from the total of 1,082 clinical
isolates tested versus 11 antimicrobial agents with the GNS-F6
card was 4.5% (1.7% very major, 0.9% major, and 1.9% minor
errors).
The distributions of errors in each of the three error cate-
gories were roughly equivalent for most antimicrobial agents
(Table 2). Essentially the same observations could be made
from the results of testing of a set of 200 common challenge
strains in the four laboratories (data not shown).
As seen in Table 1, five species were tested in numbers large
enough to permit analysis individually: E. coli (n 5 163 total
clinical isolates in all four laboratories), Proteus mirabilis (n 5
127), Klebsiella pneumoniae (n 5 154), Enterobacter cloacae
(n 5 144), and P. aeruginosa (n 5 158). Large numbers of these
species were also included in the challenge set. In eight cases,
individual organism-antimicrobial combinations yielded dis-
crepancy rates much higher than the total category error rates
calculated from the entire organism collection. For E. cloacae
and the indicated agents, the rates were as follows: ampicillin-
sulbactam, 5.6% very major errors; aztreonam, 4.2% very ma-
jor errors; ticarcillin, 7.6% very major errors; and ticarcillin-
clavulanate, 7.6% very major errors. For P. aeruginosa, the
rates were as follows: mezlocillin, 5.1% very major errors;
TABLE 1. Clinical isolates and common stock strains examined by both Vitek GNS-F6 and broth microdilution methods
Organism
No. of strains
Laboratory A Laboratory B Laboratory C Laboratory D Common stock
Escherichia coli 41 40 40 42 30
Proteus mirabilis 36 40 40 11 16
Klebsiella pneumoniae 36 40 40 38 20
Enterobacter cloacae 33 50 40 21 20
Pseudomonas aeruginosa 36 40 39 43 32
Shigella sonnei 2 26 1
Shigella boydii 1
Shigella dysenteriae 1
Shigella flexneri 1 5
Salmonella spp. 1 1 15
Citrobacter amalonaticus 1
Citrobacter freundii 6 19 11 13
Citrobacter koseri 6 7 1 1
Klebsiella oxytoca 1 2 20 10 6
Klebsiella ozaenae 1
Enterobacter aerogenes 10 24 15 2 18
Enterobacter agglomerans 1 1 1 2
Enterobacter amnigenus 1
Enterobacter sakazakii 1
Hafnia alvei 1 1
Serratia liquefaciens 1 3
Serratia marcescens 5 20 18 15
Serratia odorifera 1
Proteus vulgaris 3 3 6 8
Providencia rettgeri 1 1 6 9
Providencia rustigianni 2
Providencia stuartii 25 7 3
Pseudomonas alcalifaciens 1
Morganella morganii 5 6 12 2 2
Lecelercia adecarboxylata 1
Acinetobacter calcoaceticus 2 3 7
Acinetobacter lwoffii 1
Aeromonas hydrophilia 2
Total 231 320 299 232 200
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ticarcillin, 5.7% very major errors; and ticarcillin-clavulanate,
6.9% very major errors. The rate for P. mirabilis with imi-
penem was 12.6% major errors, and that for K. pneumoniae
with ofloxacin was 3.9% major errors. These values are based
on results obtained with clinical isolates. Again, with one ex-
ception, the same general results were obtained with the com-
mon challenge set of organisms (data not shown). The excep-
tion was K. pneumoniae when tested against ofloxacin. As
noted above, with clinical isolates, the major error rate with
this combination was 3.9%; with organisms from the challenge
set, the major error rate was 12.5%. We were unable to explain
this difference. Initially, 140 of the 299 clinical isolates in lab-
oratory C and 30 of 200 strains in the challenge set were
inadvertently tested with the GNS-F6 card using an inoculum
fourfold higher than that recommended by the manufacturer.
When this error was discovered, these 170 strains were retested
with a suitable inoculum density, and it is the results of this
second testing that are presented in Table 2 and discussed
above.
Initial testing of 140 clinical isolates with an inappropriately
high inoculum in laboratory C led to significantly higher major
error rates with aztreonam (16.7%), imipenem (4.0%), mez-
locillin (8.4%), and piperacillin (8.4%). Disproportionately
high minor error rates were observed with ampicillin-sulbac-
tam (10%), imipenem (3.3%), mezlocillin (11.0%), piperacillin
(8.4%), ticarcillin (3.3%), and ticarcillin-clavulanate (5.7%).
Among the total of 125 minor errors observed in laboratory C
with these six antimicrobial agents, in 104 cases (83.2%), the
GNS-F6 card yielded an R or an I result, whereas the broth
microdilution MIC categorized the isolate as I or S, respec-
tively. The same patterns were noted with the 30 isolates from
the common challenge set that were tested initially with an
inoculum fourfold higher than that recommended by the man-
ufacturer (data not shown).
All of the clinical isolates that had yielded very major (n 5
197) or major (n 5 113) errors with any antimicrobial agent
when tested with the GNS-F6 card in the four participating
laboratories (Table 2) were repeat tested with the GNS-F6
card in the coordinating study center, UMMC. In 64 cases
(32.5%), among the isolates that had initially yielded 197 very
major errors, a false S result was again observed on repeat
GNS-F6 testing. In 130 cases (66%) among these same iso-
lates, a correct R result was obtained. Forty-four (33.1%) of
the 133 major errors were corroborated upon repeat GNS-F6
testing; in 86 cases (64.7%), a correct S result was obtained.
Repeat broth microdilution MIC determinations were also
performed for the isolates that had yielded 197 very major
errors with the GNS-F6 card as well as the isolates that yielded
133 major errors. In 189 (95.9%) and 123 (92.5%) cases, re-
spectively, the repeat MIC was found to be the same or within
61 dilution increment of the initial MIC.
DISCUSSION
The results of this investigation indicate that the currently
available bioMerieux Vitek system, when used in conjunction
with the GNS-F6 card according to the manufacturer’s recom-
mendations, provides accurate susceptibility test results with
numerous Enterobacteriaceae and P. aeruginosa versus ampicil-
lin, ampicillin-sulbactam, aztreonam, ciprofloxacin, imipenem,
mezlocillin, ofloxacin, piperacillin, ticarcillin, ticarcillin-clavu-
lanate, and TMP-SMX. An overall category error rate of
,10% has been established as a standard of performance for
susceptibility tests (17). Included in this target percentage are
very major error rates of #1.5% and major error rates of
#3.0% (17). When analyzed by antimicrobial agent without
respect to the organism tested, the total aggregate very major
rate was found to exceed the 1.5% standard in five cases, i.e.,
ampicillin-sulbactam (4.1%), mezlocillin (1.8%), piperacillin
(1.8%), ticarcillin (2.6%), and ticarcillin-clavulanate (4.1%). In
no case did the total major error rate exceed 3.0% or was the
total aggregate error rate greater than 10%. Indeed, in most
instances, the error rates obtained with the study agents with
the Vitek system and the GNS-F6 card were well below these
limits.
Certain specific organism-antimicrobial combinations ap-
peared to yield disproportionately high very major or major
error rates. In the first category were E. cloacae versus ampi-
cillin-sulbactam, aztreonam, ticarcillin, and ticarcillin-clavu-
lanate and P. aeruginosa versus mezlocillin, ticarcillin, and ti-
carcillin-clavulanate. In the second category were P. mirabilis
versus imipenem and K. pneumoniae versus ofloxacin. These
observations are generally consistent with several previously
published evaluations of the Vitek system (6, 9–11, 19–21, 28,
TABLE 2. Results of comparisons between Vitek GNS-F6 results and broth microdilution MIC determinations with clinical isolates of
Enterobacteriaceae and P. aeruginosa tested in four laboratories versus 11 antimicrobial agents
Antimicrobial
No. (%) of errorsa:
Laboratory A (n 5 231) Laboratory B (n 5 320) Laboratory C (n 5 299) Laboratory D (n 5 232) Total (n 5 1,082)
VM M mi VM M mi VM M mi VM M mi VM M mi
Ampicillin 0 (0.0) 8 (3.5) 3 (1.3) 4 (1.3) 6 (1.9) 2 (0.6) 7 (2.3) 0 (0.0) 2 (0.7) 2 (0.9) 0 (0.0) 1 (0.4) 13 (1.2) 14 (1.3) 8 (0.7)
Ampicillin-
sulbactam
11 (4.8) 1 (0.4) 5 (2.2) 11 (3.4) 1 (0.3) 13 (4.1) 18 (6.0) 0 (0.0) 17 (5.7) 5 (2.2) 1 (0.4) 8 (3.4) 45 (4.1) 3 (0.3) 43 (4.0)
Aztreonam 5 (2.1) 11 (4.8) 5 (2.1) 5 (1.6) 8 (2.5) 8 (2.5) 4 (1.3) 0 (0.0) 0 (0.0) 2 (0.9) 1 (0.4) 1 (0.4) 16 (1.5) 20 (1.8) 14 (1.3)
Ciprofloxacin 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 3 (0.9) 6 (1.9) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.4) 4 (1.7) 0 (0.0) 5 (0.4) 11 (1.0)
Imipenem 0 (0.0) 9 (3.9) 3 (1.3) 0 (0.0) 9 (2.8) 3 (0.9) 0 (0.0) 4 (1.3) 2 (0.7) 1 (0.4) 6 (2.6) 0 (0.0) 1 (0.09) 28 (2.6) 8 (0.7)
Mezlocillin 2 (0.9) 7 (3.0) 7 (3.0) 7 (2.2) 1 (0.3) 11 (3.4) 4 (1.3) 1 (0.3) 9 (3.0) 6 (2.6) 0 (0.0) 12 (5.2) 19 (1.8) 9 (0.8) 39 (3.6)
Ofloxacin 0 (0.0) 2 (0.9) 1 (0.4) 0 (0.0) 12 (3.8) 7 (2.2) 0 (0.0) 1 (0.3) 1 (0.3) 0 (0.0) 4 (1.7) 0 (0.0) 0 (0.0) 19 (1.8) 9 (0.8)
Piperacillin 5 (2.2) 5 (2.2) 7 (3.0) 8 (2.5) 4 (1.3) 11 (3.4) 0 (0.0) 1 (0.3) 18 (6.0) 7 (3.0) 1 (0.4) 7 (3.0) 20 (1.8) 11 (1.0) 43 (4.0)
Ticarcillin 6 (2.6) 3 (1.3) 2 (0.9) 11 (3.4) 3 (0.9) 5 (1.6) 5 (1.7) 0 (0.0) 6 (2.0) 6 (2.6) 1 (0.4) 3 (1.3) 28 (2.6) 7 (0.6) 16 (1.5)
Ticarcillin-
clavulanate
6 (2.6) 0 (0.0) 4 (1.7) 16 (5.0) 4 (1.3) 4 (1.3) 8 (2.7) 0 (0.0) 7 (2.3) 14 (6.0) 0 (0.0) 8 (3.4) 44 (4.1) 4 (0.3) 23 (2.1)
TMP/SMX 1 (0.4) 2 (0.9) 0 (0.0) 4 (1.3) 5 (1.6) 0 (0.0) 0 (0.0) 3 (1.0) 0 (0.0) 6 (2.6) 3 (1.3) 0 (0.0) 11 (1.0) 13 (1.2) 0 (0.0)
Total 36 (1.4) 48 (1.9) 38 (1.5) 66 (1.9) 56 (1.6) 70 (2.0) 46 (1.4) 11 (0.3) 62 (1.9) 49 (1.9) 18 (0.7) 44 (1.7) 197 (1.7) 133 (1.1) 214 (1.8)
a VM, very major, M, major; mi, minor.
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32). The higher very major error rate observed with P. aerugi-
nosa and mezlocillin, ticarcillin, and ticarcillin-clavulanate may
have been influenced by the fact that no intermediate MIC
interpretive category has been established for these agents
versus P. aeruginosa (18). As a result, even a 1-dilution MIC
discrepancy could yield a very major error. The problem of
false resistant ofloxacin results with K. pneumoniae with the
GNS-F6 card has been previously described in the literature
(5). The problem was solved by a manufacturer reformulation
of the ofloxacin used in the test card (5). Updated cards con-
taining the reformulated ofloxacin (i.e., GNS-F8) are now
commercially available.
This study was intentionally conducted in clinical microbiol-
ogy laboratories of four distinctly different hospital settings, an
acute-care community hospital, a Veterans Administration
medical center, a tertiary-care referral hospital in an academic
medical center, and a pediatric hospital. It was reasoned that
this diversity would provide the most rigorous challenge of the
Vitek system. Surprisingly little interlaboratory variability was
observed. This suggests that the utility of the Vitek suscepti-
bility test system is not influenced by patient demographics or
geographic location.
Finally, the results of this study underscore the importance
of inoculum size as a determinant in the accuracy of results
obtained with the Vitek system when Enterobacteriaceae and P.
aeruginosa are tested. Not surprisingly, the antimicrobial
agents most effected by a high inoculum were cell wall-active
compounds, i.e., aztreonam, mezlocillin, piperacillin, imi-
penem, ampicillin-sulbactam, ticarcillin-clavulanate, and ticar-
cillin. Inoculum-related errors with these agents manifest as
either false resistance, a major error, or minor errors in the
direction of false resistance. An inoculum effect with b-lactam
antimicrobial agents has been well documented. It is possible
that two recent reports of excessive numbers of major errors
when the Vitek system and the GNS-F6 card were used to test
aztreonam and imipenem versus Enterobacteriaceae and P.
aeruginosa were the result of an inoculum effect (1, 15). In the
current study, when care was exercised to use an inoculum
equivalent to that recommended by the manufacturer, accu-
rate results were obtained with these agents.
In conclusion, the results of this multicenter clinical labora-
tory evaluation of the Vitek system and the GNS-F6 card
indicate that this combination as currently formatted repre-
sents an accurate and acceptable means for performing sus-
ceptibility tests with the Enterobacteriaceae and P. aeruginosa
versus several antimicrobial agents.
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